Leap Therapeutics

04/11/2024

We’re excited to announce a $40 million equity financing. Thank you to our strategic and institutional investors for supporting our mission to develop DKN-01 to treat GI cancer patients around the world.

Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass. , April 11, 2024 /PRNewswire/ -- Leap Therapeutics, Inc.

07/13/2023

For more background on DKN-01 and our DeFianCe study in patients, read this interview with Dr. John Strickler of Duke University from earlier this year. Making a difference for CRC patients is our mission at Leap.

In an interview with Targeted Oncology, John Strickler, MD, discussed the background and goals of the DeFianCe study in the colorectal cancer space.

07/12/2023

DKN-01 is moving into a second randomized controlled trial! This time in patients. Early efficacy data and high investigator/patient enthusiasm mark another milestone for DKN-01. Thank you to everyone involved in the DeFianCe study.

CAMBRIDGE, Mass. , July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal

06/05/2023

Today at , updated data from Part A of the DisTinGuish Study of DKN-01 + BeiGene's tislelizumab + chemo in was presented as a poster and in a discussion session. https://www.leaptx.com/wp-content/uploads/2023/06/ASCO-2023-226390_A2838_poster_ppt.pdf?_gl=1*spmwai*_up*MQ..*_ga*NTI2OTQxNTU4LjE2ODU5ODk3NTQ.*_ga_SBRE9X09Y0*MTY4NTk4OTc1NC4xLjEuMTY4NTk4OTc1Ny4wLjAuMA..

05/26/2023

Join us at as we present updated data from Part A of the DisTinGuish Study! Dr. Sam Klempner will be sharing insights on DKN-01 + BeiGene's tislelizumab & chemo in patients at the poster and discussion session on Monday, June 5th, 11:30 AM CT.

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass.

04/13/2023

Our DeFianCe study aims to address the unmet medical need of CRC patients who have low response rates and PFS after 1L therapy. Part A has enrolled 33 patients to evaluate the efficacy of DKN-01, our anti-DKK1 antibody, as a potential new therapy.

CAMBRIDGE, Mass. , April 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in Part A of the Phase 2 DeFianCe study evaluating DKN-01, Leap's

04/04/2023

Check out our latest publication which demonstrates that DKK1 is a predictive biomarker for clinical response in Endometrial Cancer (EC) and suggests DKN-01 is a promising therapy for DKK1 high EC patients.https://www.leaptx.com/wp-content/uploads/2023/03/DKK1-is-a-predictive-biomarker-for-response-to-DKN-01-1.pdf

01/31/2023

Thank you Nasdaq for spreading the news of our Flame Biosciences acquisition, which brought 3 exciting pipeline assets; FL-301 CLDN18.2 mAb, FL-302 CLDN18.2/CD137 bispecific, and FL-501 GDF15 mAb as well as $50m in cash.

01/17/2023

We are pleased to announce our acquisition of Flame Biosciences bolstering our innovative oncology pipeline.

Adds FL-301, clinical stage anti-Claudin18.2 antibody, and two preclinical antibody programs to Leap's pipeline Combined cash balance of approximately $115 million enhances runway to mid-2025, fully-funding advancement of DKN-01 and FL-301 Leap to host conference call at 9:00 a.m.

11/07/2022

Join us this Thursday at SITC22 to hear about our DKN-01 preclinical colorectal cancer data and for an update on our ongoing DisTinGuish gastric cancer clinical trial: DKN-01 in combination with BeiGene's tislelizumab.

55% ORR, 73% DCR, and 7.7 month PFS in DKK1 -high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass. , Nov. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc.

10/17/2022

We are excited to announce the first patient has been enrolled into our randomized phase 2 DeFianCe study of DKN-01 in combination with bevacizumab and chemo for the 2nd line treatment of colorectal cancer.

CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the Phase 2 DeFianCe study evaluating DKN-01, Leap's

10/13/2022

Learn more about DKK1 and the mechanism of action of DKN-01 in . Check out this new publication on DKK1’s multi-pronged role in suppressing anti-tumor immunity, making it a promising target for enhancing PD-1-based therapy.

Abstract. Tumor-associated macrophages (TAMs) have key functions in promoting a suppressive tumor immune microenvironment (TIME) and immune evasion, which largely limit treatment effects of immune checkpoint inhibitors (ICIs) in different cancers, including gastric cancer (GC). Dickkopf-1 (DKK1) ass...